6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep

Zeeshan Syedain, Jay Reimer, Jillian Schmidt, Matthew Lahti, James Berry, Richard Bianco, Robert T. Tranquillo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Diseased aortic valves often require replacement, with over 30% of the current aortic valve surgeries performed in patients who will outlive a bioprosthetic valve. While many promising tissue-engineered valves have been created in the lab using the cell-seeded polymeric scaffold paradigm, none have been successfully tested long-term in the aortic position of a pre-clinical model. The high pressure gradients and dynamic flow across the aortic valve leaflets require engineering a tissue that has the strength and compliance to withstand high mechanical demand without compromising normal hemodynamics. A long-term preclinical evaluation of an off-the-shelf tissue-engineered aortic valve in the sheep model is presented here. The valves were made from a tube of decellularized cell-produced matrix mounted on a frame. The engineered matrix is primarily composed of collagen, with strength and organization comparable to native valve leaflets. In vitro testing showed excellent hemodynamic performance with low regurgitation, low systolic pressure gradient, and large orifice area. The implanted valves showed large-scale leaflet motion and maintained effective orifice area throughout the duration of the 6-month implant, with no calcification. After 24 weeks implantation (over 17 million cycles), the valves showed no change in tensile mechanical properties. In addition, histology and DNA quantitation showed repopulation of the engineered matrix with interstitial-like cells and endothelialization. New extracellular matrix deposition, including elastin, further demonstrates positive tissue remodeling in addition to recellularization and valve function. Long-term implantation in the sheep model resulted in functionality, matrix remodeling, and recellularization, unprecedented results for a tissue-engineered aortic valve.

Original languageEnglish (US)
Pages (from-to)175-184
Number of pages10
JournalBiomaterials
Volume73
DOIs
StatePublished - Dec 1 2015

Fingerprint

Aortic Valve
Sheep
Tissue
Hemodynamics
Orifices
Pressure gradient
Elastin
Histology
Tissue Engineering
Collagen
Scaffolds
Surgery
Compliance
Extracellular Matrix
DNA
Blood Pressure
Pressure
Mechanical properties
Testing

Keywords

  • Aortic valve disease
  • Decellualrized biomaterial
  • Heart valve
  • Matrix remodeling
  • Tissue engineering

Cite this

6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep. / Syedain, Zeeshan; Reimer, Jay; Schmidt, Jillian; Lahti, Matthew; Berry, James; Bianco, Richard; Tranquillo, Robert T.

In: Biomaterials, Vol. 73, 01.12.2015, p. 175-184.

Research output: Contribution to journalArticle

Syedain, Zeeshan ; Reimer, Jay ; Schmidt, Jillian ; Lahti, Matthew ; Berry, James ; Bianco, Richard ; Tranquillo, Robert T. / 6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep. In: Biomaterials. 2015 ; Vol. 73. pp. 175-184.
@article{fcf3ba92c2524a2299eaa6c15276e4f1,
title = "6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep",
abstract = "Diseased aortic valves often require replacement, with over 30{\%} of the current aortic valve surgeries performed in patients who will outlive a bioprosthetic valve. While many promising tissue-engineered valves have been created in the lab using the cell-seeded polymeric scaffold paradigm, none have been successfully tested long-term in the aortic position of a pre-clinical model. The high pressure gradients and dynamic flow across the aortic valve leaflets require engineering a tissue that has the strength and compliance to withstand high mechanical demand without compromising normal hemodynamics. A long-term preclinical evaluation of an off-the-shelf tissue-engineered aortic valve in the sheep model is presented here. The valves were made from a tube of decellularized cell-produced matrix mounted on a frame. The engineered matrix is primarily composed of collagen, with strength and organization comparable to native valve leaflets. In vitro testing showed excellent hemodynamic performance with low regurgitation, low systolic pressure gradient, and large orifice area. The implanted valves showed large-scale leaflet motion and maintained effective orifice area throughout the duration of the 6-month implant, with no calcification. After 24 weeks implantation (over 17 million cycles), the valves showed no change in tensile mechanical properties. In addition, histology and DNA quantitation showed repopulation of the engineered matrix with interstitial-like cells and endothelialization. New extracellular matrix deposition, including elastin, further demonstrates positive tissue remodeling in addition to recellularization and valve function. Long-term implantation in the sheep model resulted in functionality, matrix remodeling, and recellularization, unprecedented results for a tissue-engineered aortic valve.",
keywords = "Aortic valve disease, Decellualrized biomaterial, Heart valve, Matrix remodeling, Tissue engineering",
author = "Zeeshan Syedain and Jay Reimer and Jillian Schmidt and Matthew Lahti and James Berry and Richard Bianco and Tranquillo, {Robert T.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2015.09.016",
language = "English (US)",
volume = "73",
pages = "175--184",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - 6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep

AU - Syedain, Zeeshan

AU - Reimer, Jay

AU - Schmidt, Jillian

AU - Lahti, Matthew

AU - Berry, James

AU - Bianco, Richard

AU - Tranquillo, Robert T.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Diseased aortic valves often require replacement, with over 30% of the current aortic valve surgeries performed in patients who will outlive a bioprosthetic valve. While many promising tissue-engineered valves have been created in the lab using the cell-seeded polymeric scaffold paradigm, none have been successfully tested long-term in the aortic position of a pre-clinical model. The high pressure gradients and dynamic flow across the aortic valve leaflets require engineering a tissue that has the strength and compliance to withstand high mechanical demand without compromising normal hemodynamics. A long-term preclinical evaluation of an off-the-shelf tissue-engineered aortic valve in the sheep model is presented here. The valves were made from a tube of decellularized cell-produced matrix mounted on a frame. The engineered matrix is primarily composed of collagen, with strength and organization comparable to native valve leaflets. In vitro testing showed excellent hemodynamic performance with low regurgitation, low systolic pressure gradient, and large orifice area. The implanted valves showed large-scale leaflet motion and maintained effective orifice area throughout the duration of the 6-month implant, with no calcification. After 24 weeks implantation (over 17 million cycles), the valves showed no change in tensile mechanical properties. In addition, histology and DNA quantitation showed repopulation of the engineered matrix with interstitial-like cells and endothelialization. New extracellular matrix deposition, including elastin, further demonstrates positive tissue remodeling in addition to recellularization and valve function. Long-term implantation in the sheep model resulted in functionality, matrix remodeling, and recellularization, unprecedented results for a tissue-engineered aortic valve.

AB - Diseased aortic valves often require replacement, with over 30% of the current aortic valve surgeries performed in patients who will outlive a bioprosthetic valve. While many promising tissue-engineered valves have been created in the lab using the cell-seeded polymeric scaffold paradigm, none have been successfully tested long-term in the aortic position of a pre-clinical model. The high pressure gradients and dynamic flow across the aortic valve leaflets require engineering a tissue that has the strength and compliance to withstand high mechanical demand without compromising normal hemodynamics. A long-term preclinical evaluation of an off-the-shelf tissue-engineered aortic valve in the sheep model is presented here. The valves were made from a tube of decellularized cell-produced matrix mounted on a frame. The engineered matrix is primarily composed of collagen, with strength and organization comparable to native valve leaflets. In vitro testing showed excellent hemodynamic performance with low regurgitation, low systolic pressure gradient, and large orifice area. The implanted valves showed large-scale leaflet motion and maintained effective orifice area throughout the duration of the 6-month implant, with no calcification. After 24 weeks implantation (over 17 million cycles), the valves showed no change in tensile mechanical properties. In addition, histology and DNA quantitation showed repopulation of the engineered matrix with interstitial-like cells and endothelialization. New extracellular matrix deposition, including elastin, further demonstrates positive tissue remodeling in addition to recellularization and valve function. Long-term implantation in the sheep model resulted in functionality, matrix remodeling, and recellularization, unprecedented results for a tissue-engineered aortic valve.

KW - Aortic valve disease

KW - Decellualrized biomaterial

KW - Heart valve

KW - Matrix remodeling

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=84943577525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943577525&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2015.09.016

DO - 10.1016/j.biomaterials.2015.09.016

M3 - Article

VL - 73

SP - 175

EP - 184

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -